New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 4, 2014
09:32 EDTPTCTPTC Therapeutics announces conditional EU approval of Translarna
PTC Therapeutics announced that the European Commission has granted conditional marketing authorization for Translarna, in the European Union for the treatment of nonsense mutation Duchenne muscular dystrophy in ambulatory patients aged five years and older. The authorization allows PTC to market Translarna in the 28 countries that are Member States of the European Union, as well as European Economic Area members Iceland, Liechtenstein and Norway. As part of the conditional marketing authorization, PTC is obligated to complete its confirmatory Phase 3 trial in nmDMD and submit additional efficacy and safety data from the trial.
News For PTCT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 9, 2014
18:36 EDTPTCTPTC Therapeutics 3M share Spot Secondary priced at $36.25
Subscribe for More Information
October 8, 2014
16:25 EDTPTCTPTC Therapeutics files to sell 3M shares of common stock
Credit Suisse and Citigroup are acting as joint lead book-running managers for the offering. Cowen and Company, Deutsche Bank Securities and RBC Capital Markets are acting as book-running managers.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use